Company Revenue

The company grew more than 20% in the first quarter of 2024 but lowered its full-year guidance due to increased...

The company grew 27% in the first quarter of 2024 as it further capitalized on disruption in the spine market....

The company drove strong results for its non-surgical hyaluronic acid pain treatments and surgical bone graft substitutes....

The company grew in the high single digits for the first quarter of 2024, including above-market growth in the United...

The combined company integrated its field organizations during the first quarter and drove low-single-digit pro forma growth....

The company grew in the mid-teens for the first quarter as it surpassed the 100,000 completed procedures milestone....

The company grew 54% in the first quarter of 2024 as CERAMENT continues to attract new customers and further penetrate...

The company's recon sales grew in the high single digits on a pro forma basis as it integrates recent acquisitions....

The company grew 3.2% in the 1Q24 but achieved its mid-single-digit growth target when adjusting for currency and selling days....

The company's orthopedic sales grew in the high-single-digits for 1Q24 against massive 2023 comparisons fueled by backlogged procedures....